重新审视不明来源栓塞性卒中概念
不明来源栓塞性卒中(ESUS)概念旨在识别可能受益于直接口服抗凝药的患者,但两项大型随机试验未显示直接口服抗凝药优于阿司匹林。本文重新审视ESUS概念,探讨更特异的识别心源性栓塞病因的标准,并关注长期心脏监测检测房颤的作用及正在进行的临床试验。
要点
- ESUS概念未能准确识别应接受直接口服抗凝药的患者。
- 两项大型随机试验显示直接口服抗凝药在ESUS患者中不优于阿司匹林。
- 更特异的识别隐匿性房颤高风险患者的标准正在临床试验中测试。
核心结论
- 当前ESUS定义不能准确识别应接受直接口服抗凝药的患者,可能因隐匿性房颤发生率低于预期或抗凝药在无房颤的ESUS患者中获益较小。
研究设计与样本
- 本文为对ESUS概念的重新审视,基于两项近期大型随机试验的阴性结果及正在进行的临床试验。
主要发现
- 两项近期大型随机试验未能显示直接口服抗凝药在ESUS患者中优于阿司匹林。
- 基于阴性试验结果,对符合当前ESUS定义的患者进行长期心脏监测以检测房颤及检测房颤的临床意义重新受到关注。
临床怎么用
- 临床需重新评估ESUS患者抗凝策略,并关注长期心脏监测在检测房颤中的作用。
局限性
- 当前ESUS定义未能准确识别目标患者,隐匿性房颤发生率可能低于预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Occult atrial fibrillation (AF) is a leading cause of stroke of unclear cause. The optimal approach to secondary stroke prevention for these patients remains elusive. The term embolic stroke of undetermined source (ESUS) was coined to describe ischemic strokes in which the radiographic features demonstrate territorial infarcts resembling those seen in patients with confirmed sources of embolism but without a clear source of embolism detected. It was assumed that patients with ESUS had a high rate of occult AF and would benefit from treatment with direct oral anticoagulants, which are at least as effective as vitamin K antagonists for secondary stroke prevention in patients with AF, but with a much lower risk of intracerebral hemorrhage. Two recent large randomized trials failed to show superiority of direct oral anticoagulants over aspirin in ESUS patients. These findings prompt a reexamination of the ESUS concept, with the goal of improving specificity for detecting patients with a cardioembolic cause. Based on the negative trial results, there is renewed interest in the role of long-term cardiac monitoring for AF in patients who fit the current ESUS definition, as well as the clinical implication of detecting AF. Ongoing trials are exploring these questions. Current ESUS definitions do not accurately detect the patients who should be prescribed direct oral anticoagulants, potentially because occult AF is less common than expected in these patients and/or anticoagulants may be less beneficial in patients with ESUS but no AF than they are for patients with stroke with established AF. More specific criteria to identify patients who may be at higher risk for occult AF and reduce their risk of subsequent stroke have been developed and are being tested in ongoing clinical trials.
引用
- Albers GW, Bernstein R, Brachmann J, et al. Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke. 2021. PMID: 34192898. doi:10.1161/STROKEAHA.121.035208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。